Department of Biotechnology and Life Sciences, University of Insubria, via JH Dunant 3, 21100 Varese, Italy.
Biotechnol Adv. 2022 Jul-Aug;57:107948. doi: 10.1016/j.biotechadv.2022.107948. Epub 2022 Mar 23.
The spread of antimicrobial resistance in Gram-positive pathogens represents a threat to human health. To counteract the current lack of novel antibiotics, alternative antibacterial treatments have been increasingly investigated. This review covers the last decade's developments in using nanoparticles as carriers for the two classes of frontline antibiotics active on multidrug-resistant Gram-positive pathogens, i.e., glycopeptide antibiotics and daptomycin. Most of the reviewed papers deal with vancomycin nanoformulations, being teicoplanin- and daptomycin-carrying nanosystems much less investigated. Special attention is addressed to nanoantibiotics used for contrasting biofilm-associated infections. The status of the art related to nanoantibiotic toxicity is critically reviewed.
革兰氏阳性病原体中抗生素耐药性的传播对人类健康构成了威胁。为了应对当前新型抗生素的缺乏，人们越来越多地研究替代抗菌治疗方法。本综述涵盖了过去十年利用纳米颗粒作为两种一线抗生素（即糖肽类抗生素和达托霉素）的载体在治疗多药耐药革兰氏阳性病原体方面的最新进展。综述中大多数文献涉及万古霉素纳米制剂，而替考拉宁和达托霉素载纳米系统的研究较少。特别关注用于对抗生物膜相关感染的纳米抗生素。本文还批判性地回顾了纳米抗生素毒性的最新研究进展。
